dsip danaher Women Who Lead in Wealth Management: Dana Pointer of Preserver Partners Dana Deason - Employing U.S.

Free specialist consultation Benefits Separate from GLP-1 mechanism synergy when combined with Ozempic/Mounjaro 22.7% weight loss in CagriSema (REDEFINE-1, 68 weeks) best result among incretin therapies 10.8% in monotherapy over 26 weeks (Phase 2, Lancet 2021) In T2D on metformin: 15.6% weight, 2.2% HbA1c combined with semaglutide Does NOT cause hypoglycemia (unlike insulin and sulfonylureas) Gradual 16-week titration smooth buildup, minimal side effects Convenient weekly dosing half-life ~7 days Cardiovascular risk reduction in T2D (secondary endpoint REDEFINE-2) Alternative/addition for patients plateauing on GLP-1 monotherapy Who it's for Weight plateau on GLP-1 (Ozempic/Mounjaro) adding cagrilintide gives +610% reduction Patients who don't tolerate high GLP-1 doses lower dose + cagrilintide instead of dose increase T2D on metformin better glycemic and weight control than semaglutide-mono Biohackers / advanced users seeking maximum CagriSema protocol effect Post-surgical weight maintenance (bariatric) adjuvant against recidivism Those wanting SEPARATE appetite control mechanism without duplicating GLP-1 How to take Standard 16-week titration (Novo Nordisk Phase 3 CagriSema): Weeks 14: 0.25 mg subcutaneous once weekly

(23-7727), a Grant-in-Aid for JSPS Scientific Research (B) (20390077) to K.M

Herbert Atkinson in the UK were early adopters of prolotherapy for Joint Hypermobility Syndrome (the former name for what overlaps with hEDS), reporting that many patients achieved stability and pain relief with a regimen of injections to affected joints

Supports brain health + focus: Semax boosts cognitive clarity, neuroprotection, and BDNF (Brain-Derived Neurotrophic Factor) levels